Clinical Trials Logo

HER2 Gene Mutation clinical trials

View clinical trials related to HER2 Gene Mutation.

Filter by:

NCT ID: NCT04179656 Not yet recruiting - Solid Tumor Clinical Trials

The Basket Study of Pyrotinib Maleate for HER2-Postive Solid Tumor

Start date: December 2019
Phase: Phase 2
Study type: Interventional

This is an open-label, Phase 2 study exploring the efficacy and safety of 马来酸Pyrotinib Maleate Tablets in patients with solid tumors with activating(harmful) HER2 mutations or with HER2 gene amplification or immunohistochemical staining (IHC) assay showing HER2 is 3+ and / or fluorescence in situ hybridization (FISH) positive.

NCT ID: NCT03845270 Completed - Clinical trials for Non Small Cell Lung Cancer Metastatic

Her2-positive Lung Cancer Treated With Dedicated Drug

R2D2
Start date: May 17, 2019
Phase: Phase 2
Study type: Interventional

HER2 (erbB-2/neu) is a member of the erbB receptor tyrosine kinase family. ERBB2 gene which encodes human epidermal growth factor 2 (HER2) is a major proliferative driver activating downstream signaling through PI3K-AKT and MEK-ERK. HER2 overexpression or gene amplification is associated with sensitivity to trastuzumab and lapatinib in breast cancer. Among actual lung cancer biomarker, HER2 remains apart. HER2 involvement is known for a long time but clinical research has been stopped for many years since the first clinical trials in unselected patients were negative. Recently trastuzumab + pertuzumab + docetaxel has been tested for first-line treatment of HER2-positive metastatic breast cancer (CLEOPATRA trial). Analysis of the primary end point showed that patients who received pertuzumab, trastuzumab, and docetaxel (pertuzumab group) had a significantly longer median progression-free survival, as assessed by independent reviewers an did those who received placebo, trastuzumab, and docetaxel (control group) (hazard ratio favoring the pertuzumab group, 0.62). There is thus a strong rational for treating HER2 mutated lung cancer patient with these drugs.

NCT ID: NCT03743350 Not yet recruiting - Clinical trials for Non Small Cell Lung Cancer

NSCLC Exon 20 or HER2-activating Mutations

RAIN
Start date: February 2019
Phase: Phase 2
Study type: Interventional

Phase 2, Open Label, single treatment

NCT ID: NCT03602079 Completed - Prostate Cancer Clinical Trials

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Start date: July 16, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

Open-label, Phase I-II, first-in-human (FIH) study for A166 monotherapy in HER2-expressing or amplified patients who progressed on or did not respond to available standard therapies. Patients must have documented HER2 expression or amplification. The patient must have exhausted available standard therapies. Patients will receive study drug as a single IV infusion. Cycles will continue until disease progression or unacceptable toxicity.

NCT ID: NCT03412383 Recruiting - Breast Cancer Clinical Trials

Pyrotinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer

Start date: February 20, 2018
Phase: Phase 2
Study type: Interventional

A Phase II Study of Pyrotinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer

NCT ID: NCT02979821 Completed - HER2 Gene Mutation Clinical Trials

Poziotinib in Stage IV Lung Adenocarcinoma With HER2 Mutation (KASTT001)

Start date: October 2016
Phase: Phase 2
Study type: Interventional

In this trial, treatment efficacy and safety of Poziotinib will be assessed in patients with stage IV lung adenocarcinoma harboring HER2 mutation.